Penetration and activity of antibiotics in brain abscess

Journal of the College of Physicians and Surgeons Pakistan

Volumn 15, Issue 3, 2005, Pages 165-167

  Raza, Muhammad W ^d,e   Shad, Amjad ^a   Pedler, Steve J ^b   Karamat, Karamat A ^c  

^a WALSGRAVE HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c NATIONAL INSTITUTE OF HEALTH   (Pakistan)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^e Newcastle General Hospital ^*  (United Kingdom)

Author keywords

Antibiotics; Bacterial infections; Blood brain barrier; Blood cerebrospinal fluid; Brain abscess; Nervous system

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCLOXACILLIN; FOSFOMYCIN; FUSIDIC ACID; IMIPENEM; LINEZOLID; LIPID; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PLASMA PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL FLORA; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN ABSCESS; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; HUMAN; INFLAMMATION; LIPID SOLUBILITY; MEDICAL DECISION MAKING; MOLECULAR SIZE; NEUROTOXICITY; NONHUMAN; PLASMA PROTEIN BINDING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN ABSCESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 17744391088     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Infection in Neurosurgery Working Party of the British Society of Antimicrobial Chemotherapy. The rational use of antibiotics in the treatment of brain abscess. Br J Neurosurg 2000; 14: 525-30.
2. Lutsar I, Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 2000; 39: 335-43.
3. Norby R. A review of the penetration of antibiotics into CSF and its clinical significance. Scand J Infect Dis 1978; 14: 296-309.
4. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999; 13: 595-618.
5. Lutsar I, McCracken GH Jr, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998; 27: 1117-27.
6. Lorenzo AV, Spector R. The distribution of drugs in the central nervous system. Adv Exp Med Biol 1976; 69: 447-61.
7. Spector R, Lorenzo AV. Specificity of ascorbic acid transport system of the central nervous system. Am J Physiol 1974; 226: 1468-73.
8. Lo WD, Wolny A, Boesel C. Blood-brain barrier permeability in staphylococcal cerebritis and early brain abscess.J Neurosurg 1994; 80: 897-905.
9. Fenstermacher JD, Blasberg RG, Patlak CS. Methods for quantifying the transport of drugs across brain barrier systems. Pharmacol Ther 1981; 14: 217-48.
10. de Louvois J, Gortvai P, Hurley R. Antibiotic treatment of abscesses of the central nervous system. BMJ 1977; 2: 985-7.
11. Bakken JS, Bruun JN, Gaustad P, Tasker TC. Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges. Antimicrob Agents Chemother 1986; 30: 481-4.
12. Fong IW. Staphylococcal central nervous system infections treated with cloxacillin. J Antimicrob Chemother 1983; 12: 607-12.
13. Asensi V, Carton JA, Maradona JA, Asensi JM, Perez F, Redondo P, et al. Imipenem therapy of brain abscesses. Eur J Clin Microbiol Infect Dis 1996; 15: 653-7.
14. Sjolin J, Lilja A, Eriksson N, Arneborn P, Cars O. Treatment of brain abscess with cefotaxime and metronidazole: prospective study on 15 consecutive patients. Clin Infect Dis 1993; 17: 857-63.
15. Friedrich H, Haensel-Friedrich G, Langmaak H, Daschner FD. Investigations of cefuroxime levels in cerebrospinal fluid of patients with and without meningitis. Chemotherapy 1980; 26:91-7.
16. Fong IW, Tomkins KB. Penetration of ceftazidime into the cerebrospinal fluid of patients with and without evidence of meningeal inflammation. Antimicrob Agents Chemother 1984; 26:115-6.
17. Greenman RL, Arcey SM, Dickinson GM, Mokhbat JE, Sabath LD, Platt TB, et al. Penetration of aztreonam into human cerebrospinal fluid in the presence of meningeal inflammation. J Antimicrob Chemother 1980; 15: 637-40.
18. Pfeifer G, Frenkel C, Entzian W. Pharmacokinetic aspects of cerebrospinal fluid penetration of fosfomycin. Int J Clin Pharmacol Res 1985; 5: 171-4.
19. Wellman WE, Dodge HW Jr, Heilman FR, Peterson MC. Concentration of antibiotics in the brain. J Lan Clin Med 1954; 43: 275-9.
20. Gatti G, Malena M, Casazza R, Borin M, Bassetti M, Cruciani M. Penetration of clindamycin and its metabolite N-demethyl clindamycin into cerebrospinal fluid following intravenous infusion of clindamycin phosphate in patients with AIDS. Antimicrob Agents Chemother 1998; 42: 3014-7.
21. Mindermann T, Zimmerli W, Rajacic Z, Gratzl O. Penetration of fusidic acid into human brain tissue and cerebrospinal fluid. (abstract). Acta Neurochir (Wien) 1993; 121:12-4.
22. Albanese J, Leone M, Bruguerolle B, Ayem ML, Lacarelle B, Martin C. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 44: 1356-8.
23. Thea D, Barza M. Use of antibacterial agents in infections of the central nervous system. Infect Dis Clin North Am 1989; 3: 553-70.
24. Mindermann T, Zimmerli W, Gratzl O. Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother 1998; 42: 2626-9.
25. Ingham HR, Selkon JB. Metronidazole and brain abscess. Lancet 1982; 2: 613-4.
26. Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother 2003; 47: 1902-6.
27. Krueger WA, Kottler B, Will BE, Heininger A, Guggenberger H, Unertl KE. Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid. J Clin Microbiol 2004; 42: 929-32.
28. Cottagnoud PH, Tauber MG. New therapies for pneumococcal meningitis. Expert Opin Investig Drugs 2004; 13: 393-401.
29. Rodriguez-Cerrato V, McCoig CC,. Saavedra J, Barton T, Michelow IC, Hardy RD, et al. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob Agents Chemother 2003; 47: 211-5.
30. Rosenblum ML, Hoff JT, Norman D, Edwards MS, Berg BO. Non-operative treatment of brain abscesses in selected high-risk patients. J Neurosurg 1980; 52: 217-25.
31. Jansson AK, Enblad P, Sjolin J. Efficacy and safety of cefotaxime in combination with metronidazole for empirical treatment of brain abscess in clinical practice: a retrospective study of 66 consecutive cases. Eur J Clin Microbiol Infect Dis 2004; 23: 7-14.